Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 97 | — | — | Oct 6, 2022 | Nov 1, 2025 | Dec 16, 2024 | 17 | United States |
Frequency, duration, and severity of treatment-emergent adverse events (AEs)
A mTPI design will be utilized to determine the RP2D of NC410
| Arm | Type | Description |
|---|---|---|
| NC410 and pembrolizumab | EXPERIMENTAL | All participants will receive NC410 (IV) and pembrolizumab (IV) according to the treatment schedule until a reason for treatment discontinuation is reached. |
| Name | Type | Description |
|---|---|---|
| NC410 | DRUG | NC410 will be given intravenously (IV) every 2 weeks |
| pembrolizumab | DRUG | Pembrolizumab 400mg will be given IV every 6 weeks. |
Inclusion Criteria: * Be 18 years of age on day of signing informed consent. * Participant with histologically or cytologically confirmed diagnosis of the following advanced unresectable and/or metastatic solid tumors: * Phase 1b: Participants with solid tumors that are known to be associated as...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |